Cookies on PerkinElmer
PerkinElmer uses cookies to ensure that we give you the best experience possible on our website. This may include cookies from third party websites. If you continue without changing your settings, we will assume that you consent to receive cookies from this website. You can change your cookie settings at any time. To learn more, please review our cookie policy, which includes information on how to manage your cookies.

Innovators in Cancer Immunology: Squamous Cell Carcinoma

June 19, 2017

Innovators in Cancer Immunology: Squamous Cell Carcinoma


Bernard Fox, PhD
Chief, Laboratory of Molecular and Tumor Immunology,
Robert W. Franz Cancer Research Center of
Earle A. Chiles Research Institute
Providence Cancer Center
Portland, OR

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

An acknowledged pioneer and vocal advocate in the rapidly emerging cancer immunotherapy space, Bernard Fox is one of the first scientists to recognize the fit between PerkinElmer’s Phenoptics and the analytical needs in cancer immunology. Today, Dr. Fox is focusing on developing predictive biomarkers for squamous cell carcinoma of the head-and-neck cancer (SCCHN), and for melanoma. His first study focused on PD-L1 associated down regulation of immune response in SCCHN. He is also the first to publish results of an immune signature biomarker based on a full 6-plex, Opal(TM) 7-color IHC Detection Kits showing predictive power for response to adoptive T-cell therapy in melanoma.

For more information, watch our Nature On-Demand Webcast "The Beginning of the End: Immunoprofiling Coming of Age"

Read More Stories Like This One

Tracking Elusive Breast Cancer Cells

New research by PerkinElmer confirms that PD-L1 protein expression levels in human breast cancer cells can be quickly and accurately assessed directly with the A...

Innovators in Cancer Immunology: Lymphoma

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lymphoma cancer case study, Dr. Rodig uses t...

Innovators in Cancer Immunology: Lung Cancer

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a lung cancer case study, Dr. Rimm uses this i...